title: Triple reuptake inhibitors ("broad spectrum" antidepressants).
abstract: The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors.
authors: DOV Pharmaceutical, Inc., USA. pskolnick@dovpharm.com
authors: Phil
authors: P
authors: Skolnick
authors: Anthony S
authors: AS
authors: Basile
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D002986:Clinical Trials as Topic; D006801:Humans; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology*
chemical_list: C474071:1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride; D000928:Antidepressive Agents; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D014179:Neurotransmitter Uptake Inhibitors